A Randomised, Double-Blind, Parallel- Group, Multicentre, Phase II Study to Evaluate the Safety and Pharmacological Activity of the Combination of Vandetanib (100 or 300 MG/ Daily or Placebo) With Fulvestrant (Loading Dose), In Postmenopausal Advanced Breast Cancer Patients.

Trial Profile

A Randomised, Double-Blind, Parallel- Group, Multicentre, Phase II Study to Evaluate the Safety and Pharmacological Activity of the Combination of Vandetanib (100 or 300 MG/ Daily or Placebo) With Fulvestrant (Loading Dose), In Postmenopausal Advanced Breast Cancer Patients.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2016

At a glance

  • Drugs Vandetanib (Primary) ; Fulvestrant
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms ZACFAST
  • Most Recent Events

    • 02 Oct 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
    • 01 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Mar 2013 Planned end date changed from 1 Feb 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top